Obalon Therapeutics, Inc. (NASDAQ:OBLN) is a San Diego-based, vertically integrated medical technology company focused on developing and commercializing novel technologies for weight loss. Obalon has launched the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity. The Obalon management team has over 150 combined years of experience in developing and commercializing novel medical technologies with a track record of financial and clinical excellence. For more information, please visit www.obalon.com.
|Fourth Quarter 2016 Press Release|
OBLN (Common Stock) $10.21 - 0.06 (0.00%)
Data provided by Nasdaq. Minimum 15 minutes delayed.
David Moatazedi Joins Obalon Therapeutics, Inc. Board of Directors
Obalon Therapeutics, Inc. Announces Fourth Quarter and Full Year 2016 Financial Results
Obalon Therapeutics Inc Announces Fourth Quarter and Year End 2016 Financial Results Conference Call
Obalon Therapeutics, Inc. to Ring The Nasdaq Stock Market Closing Bell
|There are currently no events scheduled.|